Die Lebensqualität junger Erwachsener nach einer Wachstumshormonbehandlung im Kindesalter
Standard
Die Lebensqualität junger Erwachsener nach einer Wachstumshormonbehandlung im Kindesalter. / Quitmann, J H; Rohenkohl, A C; Kammerer, U; Schöfl, C; Bullinger-Naber, Monika; Dörr, H-G.
In: DEUT MED WOCHENSCHR, Vol. 139, No. 46, 01.11.2014, p. 2335-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Die Lebensqualität junger Erwachsener nach einer Wachstumshormonbehandlung im Kindesalter
AU - Quitmann, J H
AU - Rohenkohl, A C
AU - Kammerer, U
AU - Schöfl, C
AU - Bullinger-Naber, Monika
AU - Dörr, H-G
N1 - © Georg Thieme Verlag KG Stuttgart · New York.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - INTRODUCTION: Little is known about the health-related quality of life of young adults with childhood onset idiopathic growth hormone deficiency or neurosecretory dysfunction of growth hormone secretion, who have been treated with recombinant human growth hormone (GH).METHODS: Patients were diagnosed and treated with human growth hormone at the University Children´s Hospital in Erlangen (n=85). The data of both groups were merged for analysis, because no difference between idiopathic growth hormone deficiency and neurosecretory dysfunction of growth hormone secretion in auxological. Data were found. Health-related quality of life was cross- sectionally assessed after the end of growth hormone therapy with the Short Form-36 Health Survey and the Nottingham Health Profiles for which population based norm data are available.RESULTS: At the time of the survey, the patients (53 m, 32 f) were 23.5 ± 4.6 years old. At start of GH therapy, age was 10.5 ± 2.8 and at the end 16.3 ± 1,4 years. At start, height SDS was -3.20 ± 1.06. GH dose was 0,026 ± 0,012 mg/kg/d (daily s. c.-injections). The increase in height SDS after the end of GH therapy was 1.69 ± 1.22. Compared to the reference population, patients reported significantly lower scores on the scales energy level, vitality, social functioning, indicating a greater social isolation, a stronger emotional reaction, an increased loss of mobility and a worse psychological state.CONCLUSION: Young adults report specific impairments after completion of GH therapy.
AB - INTRODUCTION: Little is known about the health-related quality of life of young adults with childhood onset idiopathic growth hormone deficiency or neurosecretory dysfunction of growth hormone secretion, who have been treated with recombinant human growth hormone (GH).METHODS: Patients were diagnosed and treated with human growth hormone at the University Children´s Hospital in Erlangen (n=85). The data of both groups were merged for analysis, because no difference between idiopathic growth hormone deficiency and neurosecretory dysfunction of growth hormone secretion in auxological. Data were found. Health-related quality of life was cross- sectionally assessed after the end of growth hormone therapy with the Short Form-36 Health Survey and the Nottingham Health Profiles for which population based norm data are available.RESULTS: At the time of the survey, the patients (53 m, 32 f) were 23.5 ± 4.6 years old. At start of GH therapy, age was 10.5 ± 2.8 and at the end 16.3 ± 1,4 years. At start, height SDS was -3.20 ± 1.06. GH dose was 0,026 ± 0,012 mg/kg/d (daily s. c.-injections). The increase in height SDS after the end of GH therapy was 1.69 ± 1.22. Compared to the reference population, patients reported significantly lower scores on the scales energy level, vitality, social functioning, indicating a greater social isolation, a stronger emotional reaction, an increased loss of mobility and a worse psychological state.CONCLUSION: Young adults report specific impairments after completion of GH therapy.
KW - Adolescent
KW - Body Size
KW - Child
KW - Dwarfism
KW - Female
KW - Growth Hormone
KW - Human Growth Hormone
KW - Humans
KW - Male
KW - Quality of Life
KW - Treatment Outcome
KW - Young Adult
U2 - 10.1055/s-0034-1387314
DO - 10.1055/s-0034-1387314
M3 - SCORING: Zeitschriftenaufsatz
C2 - 25369043
VL - 139
SP - 2335
EP - 2338
JO - DEUT MED WOCHENSCHR
JF - DEUT MED WOCHENSCHR
SN - 0012-0472
IS - 46
ER -